» Articles » PMID: 17727305

Pharmacological Management of Cancer Pain in the Elderly

Overview
Journal Drugs Aging
Specialties Geriatrics
Pharmacology
Date 2007 Aug 31
PMID 17727305
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Existing studies indicate a high prevalence rate and poor management of cancer pain in the elderly. Pain is often considered an expected concomitant of aging, and older patients are considered more sensitive to opioids. Despite the well known pharmacokinetic changes in the elderly, the complex network of factors involved in the opioid response make the evaluation of a single element, such as age, more difficult. Notwithstanding such difficulties, appropriate analgesic treatment is able to control cancer pain in the elderly in most cases. Skills necessary to optimise pain control in older cancer patients include the ability to objectively assess functional age (not necessarily related to chronological age since the rate of decline is variable), understand the impact of coexisting conditions, carefully manage the numbers and types of drugs taken at the same time and adequately communicate with patients and relatives. The most common treatment of cancer pain consists of the use of regularly given oral analgesics. The elderly are at increased risk of developing toxicity from NSAIDs, and the overall safety of these drugs in frail elderly patients should be considered. When older patients have clear contraindications to NSAIDs, manifest signs of toxicity from these agents, or find that pain is no longer controlled with this class of drugs, opioids should be started. A variety of opioids are available, and they differ widely with respect to analgesic potency and adverse effects among the elderly. Although the aged population requires lower doses of opioids, only careful titration based on individual response can ensure the appropriate response to clinical demand. Elderly patients are potentially more likely to be affected by opioid toxicity because of the physiological changes associated with aging. Nevertheless, appropriate dosage and administration may limit these risks. Cancer patients with pain who do not respond to increasing doses of opioids because they develop adverse effects before achieving acceptable analgesia may be switched to alternative opioids. Despite the favourable effects reported with opioid switching, monitoring is crucial, particularly in the elderly or patients who are switched from high doses of opioids. Adjuvant analgesics, including antidepressants, antiepileptics, corticosteroids and bisphosphonates may help in the treatment of certain types of chronic pain. With an appropriate and careful approach, it should be possible to reduce or eliminate unrelieved cancer pain in most elderly patients and, consequently, to enhance their quality of life. Older patients with cancer should be continuously assessed for cancer pain, both before and after analgesic treatment.

Citing Articles

Influence of aging on opioid dosing for perioperative pain management: a focus on pharmacokinetics.

Mercadante S J Anesth Analg Crit Care. 2024; 4(1):51.

PMID: 39085914 PMC: 11292879. DOI: 10.1186/s44158-024-00182-2.


Current management of cancer pain in Italy: Expert opinion paper.

Marinangeli F, Saetta A, Lugini A Open Med (Wars). 2021; 17(1):34-45.

PMID: 34950771 PMC: 8651060. DOI: 10.1515/med-2021-0393.


Prescription of pain medication among older cancer patients with and without an intellectual disability: a national register study.

Segerlantz M, Axmon A, Gagnemo Persson R, Brun E, Ahlstrom G BMC Cancer. 2019; 19(1):1040.

PMID: 31684896 PMC: 6829972. DOI: 10.1186/s12885-019-6290-0.


Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.

Guitart J, Vargas M, De Sanctis V, Folch J, Salazar R, Fuentes J Drugs R D. 2019; 19(3):247-254.

PMID: 31177479 PMC: 6738361. DOI: 10.1007/s40268-019-0276-x.


The history of cancer pain and bone-targeted agents: 10 most commonly asked questions.

Vieira C, Fragoso M, Ferreira M, Pereira F, Pereira D, Medeiros R Cancer Manag Res. 2018; 11:37-46.

PMID: 30588109 PMC: 6302803. DOI: 10.2147/CMAR.S174731.


References
1.
Wong N, Jones H . An analysis of discharge drug prescribing amongst elderly patients with renal impairment. Postgrad Med J. 1998; 74(873):420-2. PMC: 2360983. DOI: 10.1136/pgmj.74.873.420. View

2.
Mercadante S, Villari P, Ferrera P, Casuccio A . Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?. Eur J Pain. 2005; 10(2):153-9. DOI: 10.1016/j.ejpain.2005.02.006. View

3.
Donner B, Zenz M, Tryba M, Strumpf M . Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996; 64(3):527-534. DOI: 10.1016/0304-3959(95)00180-8. View

4.
Skaer T . Practice guidelines for transdermal opioids in malignant pain. Drugs. 2004; 64(23):2629-38. DOI: 10.2165/00003495-200464230-00002. View

5.
Landi F, Onder G, Cesari M, Gambassi G, Steel K, Russo A . Pain management in frail, community-living elderly patients. Arch Intern Med. 2001; 161(22):2721-4. DOI: 10.1001/archinte.161.22.2721. View